13 hrs ago
Nuvilex Contracts With Clinical Network Services Pty Ltd for...
"The work we are embarking upon with CNS is an important milestone for , as it represents the next step in proving the value of our Cell-in-the-Box technology and the potential of a better treatment for pancreatic cancer," said .
Nuvilex Selects Translational Drug Development (TD2) to Advance Treatment for Pancreatic Cancer
"Our Pancreatic Cancer Research Team colleagues are enthusiastic to begin clinical trials with this approach."
OTC Daily Alert Stock Watch - Primco Management Inc.
Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com is a biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology, known as ... (more)
Doxorubicin alone or with ifosfamide for treating soft tissue sarcoma?
An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor.
Austrianova (Austria) Contracted By Nuvilex For cGMP-Compliant...
Austrianova, a leading cell encapsulation company, announced today that it has been contracted by Nuvilex, Inc. to produce living encapsulated cells to cGMP standard.
Professor Dr. Walter H. Gunzburg, Executive Chairman and Chief...
Nuvilex obtained the worldwide exclusive licenses to use the technology for the development of treatments for cancer and diabetes from SG Austria and Austrianova Singapore, respectively, in 2013.